FRIDAY, May 16, 2025 — Danish drugmaker
2025年5月16日，星期五——丹麥製藥商
Novo Nordisk
is teaming up with California-based biotech Septerna to develop new pills to treat obesity,
正在與加利福尼亞州的生物技術公司 Septerna 合作，開發治療肥胖症的新藥片，
type 2 diabetes
2型糖尿病
and other metabolic diseases.
和其他代謝性疾病。
The deal could be worth up to $2.2 billion for
這筆交易的價值可能高達22億美元
Septerna
七重奏
. This includes more than $200 million in upfront and short-term milestone payments, plus future rewards tied to research, development and sales. Septerna will also get royalties on any future product sales,
這包括超過2億美元的預付款和短期里程碑付款，以及與研發和銷售相關的未來獎勵。Septerna還將獲得任何未來產品銷售的特許權使用費。
The Wall Street Journal
《華爾街日報》
reported.
據報道。
Novo Nordisk will pay all the research and development costs for the project.
諾和諾德將支付該項目的所有研發費用。
The U.S. biotech company has developed a platform that finds and develops drugs that target special proteins called G protein-coupled receptors (GPCRs).
美國生物技術公司已經開發了一個平臺，可以尋找和開發針對特殊蛋白質——G蛋白偶聯受體（GPCRs）的藥物。
These proteins help pass chemicals from outside cells to the inside. Many major drugs on the market today also target GPCRs.
這些蛋白質幫助將細胞外的化學物質傳遞到細胞內。當今市場上的許多主要藥物也針對GPCRs。
Novo Nordisk’s best-known drug,
諾和諾德最著名的藥物，
Wegovy
諾和盈
, targets a GPCR called GLP-1. Eli Lilly’s popular weight-loss drug
，針對一種名爲GLP-1的GPCR。Eli Lilly公司流行的減肥藥
Zepbound
澤普綁定
targets both GLP-1 and another GPCR called GIP.
同時靶向GLP-1和另一個名爲GIP的GPCR。
“Septerna has demonstrated strong capabilities in GPCR drug discovery,'
“Septerna在GPCR藥物發現方面展現了強大的能力，”
Marcus Schindler
馬庫斯·辛德勒
, chief scientific officer at Novo Nordisk, told
諾和諾德的首席科學官告訴
The Wall Street Journal.
《華爾街日報》。
“We are excited about the opportunity to develop oral small molecule medicines directed at multiple targets,” he added.
“我們對開發針對多個靶點的口服小分子藥物的機會感到興奮，”他補充道。
The two companies plan four programs to create pills that target GPCRs including GLP-1, GIP and glucagon — which are important proteins involved in blood sugar and appetite control,
兩家公司計劃開展四個項目，以研發針對GPCR的藥丸，包括GLP-1、GIP和胰高血糖素——這些是參與血糖和食慾控制的重要蛋白質。
The WSJ
《華爾街日報》
said.
說。
Right now, leading weight-loss drugs must be injected into the body. Pill versions could make the drugs more convenient for patients and easier to ship and store.
目前，主流的減肥藥物必須通過注射進入體內。藥丸版本可能會讓患者使用起來更方便，也更容易運輸和儲存。
About one-third of drugs approved by the U.S. Food and Drug Administration (FDA) target GPCRs, according to Novo Nordisk. But an estimated 75% of GPCR targets have not yet been used in medicine, meaning there’s still a big opportunity for discovery.
根據諾和諾德的數據，約三分之一的美國食品藥品監督管理局（FDA）批准的藥物針對的是GPCR，但據估計，75%的GPCR靶點尚未在醫學中使用，這意味着仍有很大的發現機會。
Septerna’s stock jumped 69% in premarket trading after the deal was announced. Novo Nordisk’s stock rose 1.2% in European trading.
Septerna的股票在交易宣佈後，盤前交易中上漲了69%。諾和諾德的股票在歐洲交易中上漲了1.2%。
Whatever your topic of interest,
無論你感興趣的話題是什麼，
subscribe to our newsletters
訂閱我們的新聞通訊
to get the best of Drugs.com in your inbox.
獲取 Drugs.com 的最佳內容到您的收件箱。